ATE322290T1 - Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia - Google Patents

Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia

Info

Publication number: ATE322290T1
Authority: AT; Austria
Prior art keywords: capecitabine; cyclooxygenase; neoplasia; combination treatment; inhibitor celecoxib
Prior art date: 1998-12-23

Application number

AT99967543T

Other languages

English (en)

Inventor

John P Mckearn

Gary Gordon

James J Cunningham

Stephen T Gately

Alane T Koki

Jaime L Masferrer

Original Assignee

Searle Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-23

Filing date

1999-12-22

Publication date

2006-04-15

1999-12-22 Application filed by Searle Llc filed Critical Searle Llc

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE322290T1 publication Critical patent/ATE322290T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
230000009826 neoplastic cell growth Effects 0.000 title abstract 2
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title 1
229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 title 1
229960004117 capecitabine Drugs 0.000 title 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 title 1
229960000590 celecoxib Drugs 0.000 title 1
238000011284 combination treatment Methods 0.000 title 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
229940123038 Integrin antagonist Drugs 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000005855 radiation Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Inorganic Chemistry (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Hydrogenated Pyridines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Pyrane Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyridine Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Radiation-Therapy Devices (AREA)

AT99967543T 1998-12-23 1999-12-22 Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia ATE322290T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11378698P	1998-12-23	1998-12-23

Publications (1)

Publication Number	Publication Date
ATE322290T1 true ATE322290T1 (de)	2006-04-15

Family

ID=22351515

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99967543T ATE322290T1 (de)	1998-12-23	1999-12-22	Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia

Country Status (20)

Country	Link
US (1)	US6689787B1 (de)
EP (8)	EP1140193A2 (de)
JP (8)	JP2002532563A (de)
KR (2)	KR20010109275A (de)
CN (3)	CN1371286A (de)
AT (1)	ATE322290T1 (de)
AU (8)	AU2592600A (de)
BR (2)	BR9916536A (de)
CA (8)	CA2356459A1 (de)
CZ (2)	CZ20012321A3 (de)
DE (1)	DE69930764D1 (de)
EA (2)	EA200100573A1 (de)
HU (2)	HUP0104814A3 (de)
IL (2)	IL143870A0 (de)
MX (1)	MXPA01006499A (de)
NO (2)	NO20013156L (de)
PL (2)	PL350291A1 (de)
TR (1)	TR200102499T2 (de)
WO (8)	WO2000037107A2 (de)
ZA (2)	ZA200105055B (de)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6696449B2 (en)	1997-03-04	2004-02-24	Pharmacia Corporation	Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US7115632B1 (en) *	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6794511B2 (en)	1997-03-04	2004-09-21	G. D. Searle	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6077850A (en) *	1997-04-21	2000-06-20	G.D. Searle & Co.	Substituted benzopyran analogs for the treatment of inflammation
US20030225150A1 (en) *	1997-04-21	2003-12-04	Pharmacia Corporation	Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US20040072889A1 (en) *	1997-04-21	2004-04-15	Pharmacia Corporation	Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US7029652B2 (en) *	1998-09-16	2006-04-18	The Regents Of The University Of California	Method of treating tumors
US20020103141A1 (en) *	1998-12-23	2002-08-01	Mckearn John P.	Antiangiogenic combination therapy for the treatment of cancer
US20040053900A1 (en) *	1998-12-23	2004-03-18	Pharmacia Corporation	Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US6800646B1 (en)	1999-02-08	2004-10-05	Pharmacia Corporation	Sulfamato hydroxamic acid metalloprotease inhibitor
HRP20010660A2 (en)	1999-02-08	2005-02-28	G.D. Searle & Co	Sulfamato hydroxamic acid metalloprotease inhibitor
AU781339B2 (en) *	1999-05-12	2005-05-19	G.D. Searle & Co.	Hydroxamic acid derivatives as matrix metalloprotease inhibitors
CA2373931A1 (en)	1999-05-17	2000-11-23	Richard Love	Dfmo and celecoxib in combination for cancer chemoprevention and therapy
US7141581B2 (en)	1999-07-02	2006-11-28	Agouron Pharmaceuticals, Inc.	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
GB9920548D0 (en) *	1999-08-31	1999-11-03	Rhone Poulenc Rorer Sa	Treatment of hepatocellular carcinoma
US7465754B1 (en)	1999-09-15	2008-12-16	Wyeth	Method of potentiating chemotherapy and treating solid tumors
EP1214092A2 (de) *	1999-09-15	2002-06-19	Wyeth	Verfahren zur verstärkung der chemotherapie und behandlung von festen tumoren
JP2003514017A (ja) *	1999-11-15	2003-04-15	アドバンストリサーチアンドテクノロジーインスティテュート，インコーポレイティド	膵臓癌の治療のためのｎｓａｉｄの使用
MXPA02007249A (es)	2000-02-03	2002-12-09	Eisai Co Ltd	Inhibidor de la expresion de integrina.
WO2001064110A1 (en) *	2000-02-28	2001-09-07	Zila, Inc.	Method for detecting and killing epithelial cancer cells
IL151833A0 (en)	2000-03-24	2003-04-10	Novartis Ag	Improved treatment of neovascularization
EP1138680A1 (de) *	2000-03-29	2001-10-04	Pfizer Products Inc.	Gem substituierte Sulfonylhydroxamsäuren mit MMP inhibierender Wirkung
AU2001269821A1 (en)	2000-06-15	2001-12-24	Barbara Chen	Cycloalkyl alkanoic acids as integrin receptor antagonists
AU7311501A (en)	2000-06-29	2002-03-22	Quick Med Technologies Inc	Cosmetic composition and method
US6531494B1 (en)	2001-08-29	2003-03-11	Pharmacia Corporation	Gem-substituted αvβ3 antagonists
NZ524104A (en) *	2000-09-08	2004-12-24	Pharmacia Italia S	Exemestane as chemopreventing agent
AR034142A1 (es) *	2000-09-08	2004-02-04	Sloan Kettering Inst Cancer	Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
MXPA03006607A (es) *	2001-01-26	2003-09-22	Upjohn Co	Metodo combinado para tratar trastornos dependientes de hormonas.
IL157443A0 (en)	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
US20030105144A1 (en) *	2001-04-17	2003-06-05	Ping Gao	Stabilized oral pharmaceutical composition
JP4660067B2 (ja)	2001-04-24	2011-03-30	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	抗血管新生剤とＴＮＦαとを用いる組合せ療法
US6872730B2 (en)	2001-04-27	2005-03-29	3-Dimensional Pharmaceuticals, Inc.	Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
ES2274043T3 (es) *	2001-05-03	2007-05-16	F. Hoffmann-La Roche Ag	Combinacion de un inhibidor de gelatina con un agente antitumoral y usos de la misma.
WO2003000194A2 (en)	2001-06-21	2003-01-03	Pfizer Inc.	Thienopyridine and thienopyrimidine anticancer agents
US6683078B2 (en)	2001-07-19	2004-01-27	Pharmacia Corporation	Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AU2002328945A1 (en) *	2001-07-23	2003-02-24	Epidauros Biotechnologie Ag	Methods for improved treatment of cancer with irinotecan based on mrp1
RU2317819C2 (ru) *	2001-10-19	2008-02-27	Новартис Аг	Фармацевтическая композиция для применения в терапии злокачественных новообразований, включающая комбинацию бифосфоната, ингибитора сох-2 и таксола
US20050043409A1 (en) *	2001-10-25	2005-02-24	Chen Ying-Nan Pan	Combinations comprising a selective cyclooxygenase-2 inhibitor
WO2003047579A1 (en) *	2001-12-03	2003-06-12	Bayer Pharmaceuticals Corporation	Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20030143165A1 (en) *	2002-01-25	2003-07-31	Allan Evans	NSAID-containing topical formulations that demonstrate chemopreventive activity
GB0204756D0 (en) *	2002-02-28	2002-04-17	Novartis Ag	Organic compounds
AU2003206068A1 (en)	2002-03-01	2003-09-16	Pfizer Inc.	Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
WO2003075957A1 (en) *	2002-03-04	2003-09-18	Medimmune, Inc.	The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AU2003214108A1 (en) *	2002-03-08	2003-09-22	Novartis Ag	Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
EP1492784A4 (de)	2002-03-28	2006-03-29	Merck & Co Inc	Substituierte 2,3-diphenylpyridine
WO2003091247A2 (en)	2002-04-25	2003-11-06	Pharmacia Corporation	Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
EP1530475A2 (de) *	2002-07-17	2005-05-18	Warner-Lambert Company LLC	Pharmazeutische zusammensetzungen die allosterische carbonsäurenmetalloprotease inhibitoren und ein selektiver cyclooxygenase-2 hemmer enthalten
AU2003281169A1 (en) *	2002-07-17	2004-02-02	Warner-Lambert Company Llc	Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003250483A1 (en) *	2002-08-19	2004-03-11	Pfizer Products Inc.	Combination therapy for hyperproliferative diseases
ES2377318T3 (es)	2002-09-06	2012-03-26	Cerulean Pharma Inc.	Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
WO2004056806A1 (en)	2002-12-19	2004-07-08	Pfizer Inc.	2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
AU2004222527A1 (en) *	2003-03-18	2004-09-30	Pharmacia Italia Spa	Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor
DE10313272A1 (de) *	2003-03-24	2004-10-21	Baxter Healthcare S.A.	Verwendung von Miltefosine zur Behandlung von aktinischer oder multiplen aktinischer Keratosen
US20050043233A1 (en)	2003-04-29	2005-02-24	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
ES2275218T3 (es)	2003-05-07	2007-06-01	Osteologix A/S	Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
US7008953B2 (en)	2003-07-30	2006-03-07	Agouron Pharmaceuticals, Inc.	3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
ES2314444T3 (es)	2003-08-29	2009-03-16	Pfizer Inc.	Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
GB0321999D0 (en) *	2003-09-19	2003-10-22	Cancer Rec Tech Ltd	Anti-cancer combinations
JP5015601B2 (ja)	2003-10-21	2012-08-29	セダーズ−シナイメディカルセンター	中枢神経系の癌を含む癌の処置のための系および方法
AU2004309166B2 (en)	2003-12-23	2008-02-21	Pfizer Inc.	Novel quinoline derivatives
CA2572223C (en)	2004-06-25	2014-08-12	The Johns Hopkins University	Angiogenesis inhibitors
DE602005020465D1 (de)	2004-08-26	2010-05-20	Pfizer	Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
JP5106098B2 (ja) *	2005-02-28	2012-12-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	スルホンアミド化合物の抗癌剤との新規併用
US7399335B2 (en) *	2005-03-22	2008-07-15	H.C. Starck Inc.	Method of preparing primary refractory metal
BRPI0706540A2 (pt) *	2006-01-18	2011-03-29	Merck Patent Gmbh	terapia especìfica usando ligantes de integrina para tratar cáncer
DE102006037158A1 (de) *	2006-08-02	2008-02-14	Bioxsys Gmbh	Verfahren zur Feststellung der Sensitivität von Tumoren gegenüber Capecitabin und Testkit
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
CA2700573C (en)	2006-09-26	2016-11-22	Cedars-Sinai Medical Center	Cancer stem cell antigen vaccines and methods
CA2700436C (en)	2006-09-28	2017-04-18	John S. Yu	Cancer vaccines and vaccination methods
EP2441464B1 (de)	2007-01-18	2014-04-09	Merck Patent GmbH	Integrin-liganden zur verwendung in der behandlung von darmkrebs
EP2114461A2 (de) *	2007-01-19	2009-11-11	Mallinckrodt Inc.	Diagnostische und therapeutische cyclooxygenase-2-bindende liganden
US20080176958A1 (en)	2007-01-24	2008-07-24	Insert Therapeutics, Inc.	Cyclodextrin-based polymers for therapeutics delivery
EP2130048B1 (de) *	2007-03-23	2012-04-18	F. Hoffmann-La Roche AG	Apex als marker für lungenkrebs
CN101730706B (zh) *	2007-05-11	2015-04-15	生物科技研究有限公司	具有神经保护和增强记忆活性的受体拮抗剂
AU2008321770B2 (en) *	2007-11-16	2012-09-06	Ube Industries, Ltd.	Benzazepinone compound
JP5346957B2 (ja)	2008-01-23	2013-11-20	ヘルレフホスピタル	不特定疾患の汎用マーカーとしてのｙｋｌ−４０
WO2009092382A1 (en) *	2008-01-23	2009-07-30	Rigshospitalet, Region Hovedstaden	Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
WO2009146218A2 (en)	2008-04-18	2009-12-03	Reata Pharmaceuticals, Inc.	Compounds including an anti-inflammatory pharmacore and methods of use
PL2328923T3 (pl)	2008-09-02	2016-06-30	Cedars Sinai Medical Center	Epitopy CD133
WO2010028658A1 (en)	2008-09-15	2010-03-18	Herlev Hospital, Region Hovedstaden	Ykl-40 as a marker for gastrointestinal cancers
US11298113B2 (en)	2008-10-01	2022-04-12	Covidien Lp	Device for needle biopsy with integrated needle protection
US9782565B2 (en)	2008-10-01	2017-10-10	Covidien Lp	Endoscopic ultrasound-guided biliary access system
US8968210B2 (en)	2008-10-01	2015-03-03	Covidien LLP	Device for needle biopsy with integrated needle protection
US9186128B2 (en) *	2008-10-01	2015-11-17	Covidien Lp	Needle biopsy device
US9332973B2 (en)	2008-10-01	2016-05-10	Covidien Lp	Needle biopsy device with exchangeable needle and integrated needle protection
EP2427485B1 (de)	2009-05-07	2016-12-07	ImmunoCellular Therapeutics, Ltd.	Cd133-epitope
PT2430452E (pt) *	2009-05-14	2014-09-30	Univ Arizona State	Diagnóstico e tratamentos de carcinoma com base no genótipo odc1
JP5572996B2 (ja) *	2009-05-15	2014-08-20	宇部興産株式会社	ベンズアゼピノン化合物を有効成分として含有する医薬
CN102448497A (zh)	2009-05-25	2012-05-09	默克专利有限公司	在癌症治疗中的西仑吉肽的持续给药
EP4166558A1 (de)	2010-02-12	2023-04-19	Pfizer Inc.	Salze und polymorphe von 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on
US8515525B2 (en) *	2011-08-16	2013-08-20	Women's Imaging Solutions Enterprises Llc	Skin adhesive agent for mammography procedures
CA2856329A1 (en)	2011-11-17	2013-05-23	Glia Sp Z.O.O.	Compositions and methods for treating glioma
WO2014015054A1 (en)	2012-07-18	2014-01-23	Saint Louis University	Beta amino acid derivatives as integrin antagonists
US8716226B2 (en)	2012-07-18	2014-05-06	Saint Louis University	3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
US20140094432A1 (en)	2012-10-02	2014-04-03	Cerulean Pharma Inc.	Methods and systems for polymer precipitation and generation of particles
TWI646091B (zh)	2012-12-28	2019-01-01	日商衛斯克慧特股份有限公司	鹽類及晶形
ES2662333T3 (es)	2013-02-14	2018-04-06	Immunocellular Therapeutics Ltd.	Vacunas contra el cáncer y métodos de vacunación
WO2014127785A1 (en)	2013-02-20	2014-08-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014150996A1 (en) *	2013-03-15	2014-09-25	Cba Pharma, Inc.	Cancer treatment
SI3050878T1 (sl)	2013-09-24	2022-01-31	Fujifilm Corporation	Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te
WO2015048467A1 (en) *	2013-09-27	2015-04-02	Cerulean Pharma Inc.	Treatment of cancer
US10421971B2 (en)	2014-01-15	2019-09-24	The University Of Chicago	Anti-tumor therapy
JP6621477B2 (ja)	2014-12-18	2019-12-18	ファイザー・インク	ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
MA43114A (fr)	2015-10-30	2018-09-05	Cancer Prevention Pharmaceuticals Inc	Formulation combinée à dose fixe d'éflornithine et sulindac
US9782370B2 (en) *	2015-12-21	2017-10-10	Gongwin Biopharm Holdings Co., Ltd.	Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
WO2017117130A1 (en)	2015-12-28	2017-07-06	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
SG11201805387RA (en)	2015-12-30	2018-07-30	Univ Saint Louis	Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
WO2017155935A1 (en) *	2016-03-07	2017-09-14	The Johns Hopkins University	Pharmaceutical agents targeting cancer stem cells
US20170273926A1 (en) *	2016-03-24	2017-09-28	Orbus Therapeutics, Inc.	Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
UA124972C2 (uk)	2016-07-29	2021-12-22	Янссен Фармацевтика Нв	Способи лікування раку передміхурової залози
US10668039B2 (en)	2016-09-02	2020-06-02	The Children's Medical Center Corporation	Methods for treatment of adenoid cystic carcinoma
IL314380A (en)	2016-10-06	2024-09-01	Orbus Therapeutics Inc	Preparations for administration of aflornithine
CN106389429A (zh) *	2016-12-02	2017-02-15	郑州莉迪亚医药科技有限公司	一种治疗老年痴呆症的西药组合物及其应用
WO2019040319A1 (en) *	2017-08-25	2019-02-28	The Regents Of The University Of California	METHODS OF ENHANCING ANTICANCER CHEMOTHERAPY
CN111777615B (zh) *	2020-07-20	2022-04-19	济南大学	一种检测环氧合酶2的光动力治疗探针及其制备
CN114767868B (zh) *	2022-03-30	2023-04-18	宁夏医科大学	Cox-2抑制剂与化疗药物在制备抗肿瘤药物中的应用
WO2024184889A1 (en) *	2023-03-08	2024-09-12	Ariel Scientific Innovations Ltd.	Methods of treating
US12605349B2 (en)	2024-09-05	2026-04-21	Orbus Therapeutics, Inc.	Methods of treating grade 3 astrocytoma

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2465486A1 (fr)	1979-09-21	1981-03-27	Roussel Uclaf	Nouvelle application utilisant la lh-rh ou des agonistes
DE3121153A1 (de)	1981-05-22	1982-12-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	"verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4659695A (en)	1985-02-08	1987-04-21	Fernand Labrie	Method of treatment of prostate cancer
US4760053A (en)	1984-08-02	1988-07-26	Fernand Labrie	Combination therapy for selected sex steroid dependent cancers
US4775660A (en)	1984-08-02	1988-10-04	Fernand Labrie	Treatment of breast cancer by combination therapy
US5039805A (en)	1988-12-08	1991-08-13	Hoffmann-La Roche Inc.	Novel benzoic and phenylacetic acid derivatives
US5084466A (en)	1989-01-31	1992-01-28	Hoffmann-La Roche Inc.	Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en)	1989-02-23	2001-11-20	Thomas Weller	Glycine derivatives
US5686566A (en)	1989-06-16	1997-11-11	Cor Therapeutics, Inc.	Platelet aggregation inhibitors
US5061693A (en)	1989-07-28	1991-10-29	Merck & Co., Inc.	Fibrinogen receptor antagonists
CA2037153A1 (en)	1990-03-09	1991-09-10	Leo Alig	Acetic acid derivatives
US5612311A (en)	1990-04-06	1997-03-18	La Jolla Cancer Research Foundation	Method and composition for treating thrombosis
US5721210A (en)	1990-07-09	1998-02-24	Tanabe Seiyaku Co., Ltd.	Cyclic cell adhesion modulation compounds
US5229366A (en)	1990-10-23	1993-07-20	Fuji Photo Film Co., Ltd.	Peptide-containing polyethylene glycol derivatives and application thereof
AU646966B2 (en)	1991-08-23	1994-03-10	Takeda Chemical Industries Ltd.	2-piperazinone compounds, their production and use
US5674863A (en)	1991-10-18	1997-10-07	Genentech, Inc.	Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
CA2078817A1 (en)	1991-10-18	1993-04-19	Beat A. Imhof	Anti-.alpha.6-integrin-antibodies
JPH07103148B2 (ja)	1991-12-16	1995-11-08	株式会社ディ・ディ・エス研究所	アントラサイクリン−マクロライド複合体
US5965132A (en)	1992-03-05	1999-10-12	Board Of Regents, The University Of Texas System	Methods and compositions for targeting the vasculature of solid tumors
US5225531A (en)	1992-04-09	1993-07-06	Washington University	Hexapeptide Lys Gly Ala Gly Asp Val
US5491129A (en)	1992-07-30	1996-02-13	Yeda Research And Development Co. Ltd.	Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
WO1994007481A1 (en) *	1992-10-02	1994-04-14	Merck & Co., Inc.	N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents
JPH06116289A (ja)	1992-10-09	1994-04-26	Fuji Photo Film Co Ltd	細胞接着性ペプチド配列複合体とその用途
EP0671911A4 (de) *	1992-11-25	1996-08-21	Merck & Co Inc	Carboxypeptidyl-derivate als antidegenerative wirkstoffe.
TW301607B (de)	1993-03-09	1997-04-01	Takeda Pharm Industry Co Ltd
DE4310632A1 (de)	1993-04-01	1994-10-06	Merck Patent Gmbh	Lineare Adhäsionsinhibitoren
DE4310643A1 (de)	1993-04-01	1994-10-06	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
DK0623615T3 (da)	1993-05-01	1999-12-13	Merck Patent Gmbh	Adhæsionsreceptor-antagonister
DE4332384A1 (de)	1993-09-23	1995-03-30	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten III
US5536814A (en)	1993-09-27	1996-07-16	La Jolla Cancer Research Foundation	Integrin-binding peptides
DE4336758A1 (de)	1993-10-28	1995-05-04	Merck Patent Gmbh	Lineare Adhäsionsinhibitoren
PT656348E (pt)	1993-12-03	2000-10-31	Hoffmann La Roche	Derivados do acido acetico como medicamentos
JP3235319B2 (ja)	1994-01-14	2001-12-04	大正製薬株式会社	チアゾリン誘導体
JP3750144B2 (ja)	1994-01-14	2006-03-01	大正製薬株式会社	３−アリールチアゾリン誘導体
DE4405378A1 (de)	1994-02-19	1995-08-24	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
JPH07285992A (ja)	1994-02-25	1995-10-31	Snow Brand Milk Prod Co Ltd	新規ペプチド
US5753230A (en) *	1994-03-18	1998-05-19	The Scripps Research Institute	Methods and compositions useful for inhibition of angiogenesis
US5770565A (en)	1994-04-13	1998-06-23	La Jolla Cancer Research Center	Peptides for reducing or inhibiting bone resorption
DE4415310A1 (de)	1994-04-30	1995-11-02	Merck Patent Gmbh	Cyclopeptide
JPH10501222A (ja)	1994-05-27	1998-02-03	メルクエンドカンパニーインコーポレーテッド	破骨細胞仲介骨吸収を抑制するための化合物
US5990112A (en) *	1996-06-18	1999-11-23	Affymax Technologies N.V.	Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
US5510332A (en)	1994-07-07	1996-04-23	Texas Biotechnology Corporation	Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US5464855A (en)	1994-08-09	1995-11-07	Warner-Lambert Company	Thiophene-2-carboxamidotetrazoles and pharmaceutical use thereof
US5639726A (en)	1994-09-30	1997-06-17	The Regents Of The University Of Michigan	Peptide mediated enhancement of thrombolysis methods and compositions
DK0710657T3 (da)	1994-11-02	1999-05-25	Merck Patent Gmbh	Adhæsionsreceptor-antagonister
DE4439846A1 (de)	1994-11-08	1996-05-09	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
US5574026A (en)	1994-12-13	1996-11-12	American Cyanamid Company	Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
JPH08183752A (ja)	1994-12-28	1996-07-16	Sumitomo Pharmaceut Co Ltd	シクロヘキサン誘導体
JPH08183788A (ja)	1994-12-28	1996-07-16	Sumitomo Pharmaceut Co Ltd	１−オキサ−６−アザスピロ〔２．５〕オクタン誘導体
DE19504954A1 (de)	1995-02-15	1996-08-22	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
DE19516483A1 (de)	1995-05-05	1996-11-07	Merck Patent Gmbh	Adhäsionsrezeptor-Antagonisten
US5817750A (en)	1995-08-28	1998-10-06	La Jolla Cancer Research Foundation	Structural mimics of RGD-binding sites
US6100423A (en)	1995-08-30	2000-08-08	G. D. Searle & Co.	Amino benzenepropanoic acid compounds and derivatives thereof
US6013651A (en)	1995-08-30	2000-01-11	G. D. Searle & Co.	Meta-azacyclic amino benzoic acid compounds and derivatives thereof
IL123164A (en)	1995-08-30	2001-03-19	Searle & Co	Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them
DE19534016A1 (de)	1995-09-14	1997-03-20	Merck Patent Gmbh	Biotinderivate
DE19534177A1 (de)	1995-09-15	1997-03-20	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
EP0765660A3 (de)	1995-09-28	1998-09-23	Takeda Chemical Industries, Ltd.	Mikrokapseln enthaltend 2-Piperazinon-1-essigsäure Verbindungen
DE19539091A1 (de)	1995-10-20	1997-04-24	Thomae Gmbh Dr K	5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
DE69625622T2 (de)	1995-10-25	2003-08-14	Senju Pharmaceutical Co., Ltd.	Angiogenese Inhibitoren
ES2233275T3 (es) *	1995-12-08	2005-06-16	Agouron Pharmaceuticals, Inc.	Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
US5760028A (en)	1995-12-22	1998-06-02	The Dupont Merck Pharmaceutical Company	Integrin receptor antagonists
ES2171768T3 (es)	1996-03-20	2002-09-16	Hoechst Ag	Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
DE19626701A1 (de)	1996-07-03	1998-01-08	Hoechst Ag	Neue Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE69710319T2 (de)	1996-03-29	2002-08-14	G.D. SEARLE & CO., CHICAGO	Para-substituierte phenylpropansäure derivate als integrin-antagonisten
ES2160949T3 (es)	1996-03-29	2001-11-16	Searle & Co	Derivados de fenilen-sulfonamida sustituidos en meta.
DK0894084T3 (da)	1996-03-29	2002-10-14	Searle & Co	Kanelsyrederivater og deres anvendelse som integrinantagonister
DE69706407T2 (de)	1996-03-29	2002-05-29	G.D. Searle & Co., Chicago	META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
WO1997036858A1 (en)	1996-03-29	1997-10-09	G.D. Searle & Co.	Cyclopropyl alkanoic acid derivatives
DE19613933A1 (de)	1996-04-06	1997-10-09	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
US5925655A (en)	1996-04-10	1999-07-20	Merck & Co., Inc.	αv β3 antagonists
WO1997041844A1 (en) *	1996-05-09	1997-11-13	Alcon Laboratories, Inc.	Combinations of angiostatic compounds
DE19654483A1 (de)	1996-06-28	1998-01-02	Merck Patent Gmbh	Phenylalanin-Derivate
EP0912495B1 (de)	1996-07-12	2001-11-21	G.D. SEARLE & CO.	Asymmetrische synthese von chiralen beta-aminosäuren
DE19629817A1 (de)	1996-07-24	1998-01-29	Hoechst Ag	Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629816A1 (de)	1996-07-24	1998-01-29	Hoechst Ag	Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
UA60311C2 (uk) *	1996-10-02	2003-10-15	Смітклайн Бічам Корпорейшн	Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
DE69729946T2 (de) *	1996-10-15	2005-01-20	G.D. Searle Llc	Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
US5919792A (en)	1996-10-30	1999-07-06	Merck & Co., Inc.	Integrin antagonists
BR9713522A (pt) *	1996-11-19	2000-03-21	Searle & Co	Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
DE69739295D1 (de)	1996-12-09	2009-04-23	Merck Patent Gmbh	Löslicher, rekombinanter alphaV beta3 Adhäsionsrezeptor
DE19653647A1 (de)	1996-12-20	1998-06-25	Hoechst Ag	Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653646A1 (de)	1996-12-20	1998-06-25	Hoechst Ag	Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653645A1 (de)	1996-12-20	1998-06-25	Hoechst Ag	Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US5837696A (en) *	1997-01-15	1998-11-17	The Research Foundation Of State University Of New York	Method of inhibiting cancer growth
JP2001509176A (ja) *	1997-01-17	2001-07-10	メルクエンドカンパニーインコーポレーテッド	インテグリンアンタゴニスト
US6017925A (en) *	1997-01-17	2000-01-25	Merck & Co., Inc.	Integrin antagonists
WO1999021583A1 (en) *	1997-10-29	1999-05-06	Warner-Lambert Company	Method of inhibiting metastases of cancer cells
WO1999025687A1 (en) *	1997-11-14	1999-05-27	G.D. Searle & Co.	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
EA003095B1 (ru) *	1997-12-17	2002-12-26	Мерк Энд Ко., Инк.	Антагонисты рецепторов интегринов
NZ333399A (en) *	1997-12-24	2000-05-26	Sankyo Co	Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
SI0928793T1 (en)	1998-01-02	2002-10-31	F. Hoffmann-La Roche Ag	Thiazole derivatives
US6372719B1 (en) *	1998-03-04	2002-04-16	Jay Cunningham	ανβ3 integrin antagonists in combination with chemotherapeutic agents
KR20010042614A (ko) *	1998-04-10	2001-05-25	윌리암스 로저 에이	비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체
WO2000006169A1 (en) *	1998-07-29	2000-02-10	Merck & Co., Inc.	Integrin receptor antagonists
US6277878B1 (en) *	1998-09-07	2001-08-21	Pfizer Inc	Substituted indole compounds as anti-inflammatory and analgesic agents

1999
- 1999-12-22 AU AU25926/00A patent/AU2592600A/en not_active Abandoned
- 1999-12-22 CA CA002356459A patent/CA2356459A1/en not_active Abandoned
- 1999-12-22 JP JP2000589217A patent/JP2002532563A/ja active Pending
- 1999-12-22 AU AU23805/00A patent/AU783992B2/en not_active Ceased
- 1999-12-22 AU AU27136/00A patent/AU2713600A/en not_active Abandoned
- 1999-12-22 KR KR1020017008113A patent/KR20010109275A/ko not_active Ceased
- 1999-12-22 JP JP2000590666A patent/JP2002533404A/ja active Pending
- 1999-12-22 WO PCT/US1999/030776 patent/WO2000037107A2/en not_active Ceased
- 1999-12-22 WO PCT/US1999/030670 patent/WO2000038665A2/en not_active Ceased
- 1999-12-22 CN CN99816333A patent/CN1371286A/zh active Pending
- 1999-12-22 HU HU0104814A patent/HUP0104814A3/hu unknown
- 1999-12-22 AT AT99967543T patent/ATE322290T1/de not_active IP Right Cessation
- 1999-12-22 WO PCT/US1999/030699 patent/WO2000038718A2/en not_active Ceased
- 1999-12-22 IL IL14387099A patent/IL143870A0/xx unknown
- 1999-12-22 BR BR9916536-8A patent/BR9916536A/pt not_active IP Right Cessation
- 1999-12-22 AU AU27135/00A patent/AU2713500A/en not_active Abandoned
- 1999-12-22 PL PL99350291A patent/PL350291A1/xx not_active Application Discontinuation
- 1999-12-22 WO PCT/US1999/030692 patent/WO2000038786A2/en not_active Ceased
- 1999-12-22 TR TR2001/02499T patent/TR200102499T2/xx unknown
- 1999-12-22 EP EP99968529A patent/EP1140193A2/de not_active Withdrawn
- 1999-12-22 AU AU22104/00A patent/AU2210400A/en not_active Abandoned
- 1999-12-22 EP EP99968942A patent/EP1140183A1/de not_active Ceased
- 1999-12-22 CA CA002356606A patent/CA2356606A1/en not_active Abandoned
- 1999-12-22 EP EP99966587A patent/EP1140178A2/de not_active Ceased
- 1999-12-22 CA CA002356748A patent/CA2356748A1/en not_active Abandoned
- 1999-12-22 AU AU25936/00A patent/AU2593600A/en not_active Abandoned
- 1999-12-22 EP EP99966594A patent/EP1140179A2/de not_active Withdrawn
- 1999-12-22 JP JP2000590668A patent/JP2002533405A/ja active Pending
- 1999-12-22 AU AU22098/00A patent/AU2209800A/en not_active Abandoned
- 1999-12-22 CZ CZ20012321A patent/CZ20012321A3/cs unknown
- 1999-12-22 JP JP2000590619A patent/JP2002533387A/ja active Pending
- 1999-12-22 WO PCT/US1999/030676 patent/WO2000038717A2/en not_active Ceased
- 1999-12-22 US US09/857,871 patent/US6689787B1/en not_active Expired - Fee Related
- 1999-12-22 CA CA002356402A patent/CA2356402A1/en not_active Abandoned
- 1999-12-22 CA CA002356302A patent/CA2356302A1/en not_active Abandoned
- 1999-12-22 EP EP99968540A patent/EP1140194A2/de not_active Withdrawn
- 1999-12-22 WO PCT/US1999/030700 patent/WO2000038719A1/en not_active Ceased
- 1999-12-22 AU AU22070/00A patent/AU2207000A/en not_active Abandoned
- 1999-12-22 EA EA200100573A patent/EA200100573A1/ru unknown
- 1999-12-22 BR BR9916518-0A patent/BR9916518A/pt not_active IP Right Cessation
- 1999-12-22 CA CA002356929A patent/CA2356929A1/en not_active Abandoned
- 1999-12-22 MX MXPA01006499A patent/MXPA01006499A/es unknown
- 1999-12-22 JP JP2000590670A patent/JP2002533407A/ja active Pending
- 1999-12-22 CA CA002356462A patent/CA2356462A1/en not_active Abandoned
- 1999-12-22 CA CA002356426A patent/CA2356426A1/en not_active Abandoned
- 1999-12-22 JP JP2000590669A patent/JP2002533406A/ja active Pending
- 1999-12-22 KR KR1020017008112A patent/KR20010110310A/ko not_active Ceased
- 1999-12-22 EA EA200100572A patent/EA006294B1/ru not_active IP Right Cessation
- 1999-12-22 EP EP99967543A patent/EP1140192B1/de not_active Expired - Lifetime
- 1999-12-22 DE DE69930764T patent/DE69930764D1/de not_active Expired - Lifetime
- 1999-12-22 HU HU0104747A patent/HUP0104747A3/hu unknown
- 1999-12-22 JP JP2000590734A patent/JP2002533422A/ja active Pending
- 1999-12-22 JP JP2000590681A patent/JP2002533416A/ja active Pending
- 1999-12-22 EP EP99968941A patent/EP1140182A2/de not_active Withdrawn
- 1999-12-22 CN CN99816063A patent/CN1398189A/zh active Pending
- 1999-12-22 PL PL99349216A patent/PL349216A1/xx not_active Application Discontinuation
- 1999-12-22 WO PCT/US1999/030693 patent/WO2000038730A2/en not_active Ceased
- 1999-12-22 CZ CZ20012320A patent/CZ20012320A3/cs unknown
- 1999-12-22 IL IL14390199A patent/IL143901A0/xx unknown
- 1999-12-22 WO PCT/US1999/030621 patent/WO2000038715A2/en not_active Ceased
- 1999-12-22 CN CN99816332A patent/CN1346282A/zh active Pending
- 1999-12-22 EP EP99966558A patent/EP1140177A2/de not_active Withdrawn
2001
- 2001-06-20 ZA ZA200105055A patent/ZA200105055B/en unknown
- 2001-06-21 ZA ZA200105120A patent/ZA200105120B/en unknown
- 2001-06-22 NO NO20013156A patent/NO20013156L/no not_active Application Discontinuation
- 2001-06-22 NO NO20013155A patent/NO20013155L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR9916536A (pt)	2002-01-02
AU2713500A (en)	2000-07-31
ZA200105055B (en)	2002-09-20
EA200100573A1 (ru)	2002-02-28
CZ20012321A3 (cs)	2002-10-16
HUP0104814A2 (hu)	2002-04-29
MXPA01006499A (es)	2002-04-08
JP2002533405A (ja)	2002-10-08
CZ20012320A3 (cs)	2002-10-16
CN1398189A (zh)	2003-02-19
JP2002532563A (ja)	2002-10-02
WO2000038730A3 (en)	2000-11-02
AU2209800A (en)	2000-07-31
CA2356426A1 (en)	2000-06-29
PL350291A1 (en)	2002-12-02
NO20013155D0 (no)	2001-06-22
CA2356748A1 (en)	2000-07-06
EP1140179A2 (de)	2001-10-10
AU2593600A (en)	2000-07-12
EP1140182A2 (de)	2001-10-10
WO2000038730A2 (en)	2000-07-06
EP1140192A2 (de)	2001-10-10
US6689787B1 (en)	2004-02-10
AU2592600A (en)	2000-07-31
CN1346282A (zh)	2002-04-24
EP1140192B1 (de)	2006-04-05
EP1140183A1 (de)	2001-10-10
EA200100572A1 (ru)	2002-02-28
CN1371286A (zh)	2002-09-25
HUP0104814A3 (en)	2003-03-28
AU2713600A (en)	2000-07-31
CA2356462A1 (en)	2000-07-06
AU783992B2 (en)	2006-01-12
EP1140193A2 (de)	2001-10-10
WO2000038786A2 (en)	2000-07-06
AU2210400A (en)	2000-07-31
EP1140177A2 (de)	2001-10-10
EA006294B1 (ru)	2005-10-27
CA2356402A1 (en)	2000-07-06
WO2000038665A2 (en)	2000-07-06
WO2000038717A2 (en)	2000-07-06
JP2002533404A (ja)	2002-10-08
KR20010109275A (ko)	2001-12-08
WO2000038719A1 (en)	2000-07-06
JP2002533422A (ja)	2002-10-08
WO2000038715A2 (en)	2000-07-06
TR200102499T2 (tr)	2001-12-21
EP1140178A2 (de)	2001-10-10
IL143901A0 (en)	2002-04-21
PL349216A1 (en)	2002-07-01
JP2002533407A (ja)	2002-10-08
NO20013156D0 (no)	2001-06-22
CA2356606A1 (en)	2000-07-06
JP2002533416A (ja)	2002-10-08
NO20013155L (no)	2001-08-22
WO2000038665A3 (en)	2000-11-16
JP2002533387A (ja)	2002-10-08
HUP0104747A3 (en)	2002-12-28
IL143870A0 (en)	2002-04-21
WO2000038718A2 (en)	2000-07-06
WO2000038786A3 (en)	2001-03-08
EP1140194A2 (de)	2001-10-10
WO2000038715A3 (en)	2001-01-04
CA2356459A1 (en)	2000-07-06
AU2207000A (en)	2000-07-31
DE69930764D1 (de)	2006-05-18
KR20010110310A (ko)	2001-12-12
HUP0104747A2 (hu)	2002-04-29
JP2002533406A (ja)	2002-10-08
NO20013156L (no)	2001-08-23
BR9916518A (pt)	2002-01-29
WO2000037107A3 (en)	2001-02-01
WO2000037107A2 (en)	2000-06-29
WO2000038718A3 (en)	2000-11-09
CA2356302A1 (en)	2000-07-06
ZA200105120B (en)	2002-01-07
WO2000038717A3 (en)	2001-02-01
AU2380500A (en)	2000-07-31
CA2356929A1 (en)	2000-07-06

Legal Events

Date	Code	Title	Description
2006-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE322290T1 (de)	2006-04-15	Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia
DK1140181T3 (da)	2005-02-14	Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi
DE69815090D1 (de)	2003-07-03	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
MXPA04002572A (es)	2004-05-31	Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
ATE404667T1 (de)	2008-08-15	Chromatin-regulatorgene
EA200400235A1 (ru)	2004-10-28	Комбинированная терапия для лечения рака
WO2004084943A8 (en)	2004-12-23	Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
DE69524623D1 (de)	2002-01-24	Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE69918972D1 (de)	2004-09-02	Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE338566T1 (de)	2006-09-15	Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
DE60137721D1 (de)	2009-04-02	Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE465728T1 (de)	2010-05-15	Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen
ATE433495T1 (de)	2009-06-15	Invasionsinhibitoren zur verwendung in der wundheilung und krebsbehandlung
DE69936779D1 (de)	2007-09-20	Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE291434T1 (de)	2005-04-15	Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE432359T1 (de)	2009-06-15	Modulation der s6-kinaseaktivität zur behandlung von adipositas
AT3848U3 (de)	2006-10-15	Verfahren zur unbaren abwicklung der mehrwertsteuer zwischen unternehmern und finanzverwaltung